TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific today and set a price target of $115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong financial performance and positive outlook. The company reported second-quarter sales and earnings per share that surpassed market expectations, with sales reaching $5.06 billion and an EPS of $0.75, both exceeding the forecasts of $4.89 billion and $0.73, respectively. This impressive performance was driven by a robust organic sales growth of 17.4%, which was significantly higher than the company’s guidance of 13-15%.
Furthermore, Boston Scientific has raised its guidance for 2025, now anticipating organic sales growth of 14-15% and an EPS range of $2.95-$2.99, up from previous estimates. The company also projects improvements in its operating margins and has adjusted its full-year expectations to account for a reduced impact from tariffs. These factors, coupled with strong performances in key segments like Cardiovascular and MedSurg, underpin Jennings’s confidence in the company’s future growth prospects, leading to the Buy rating.
In another report released today, Needham also reiterated a Buy rating on the stock with a $121.00 price target.
Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.